Comparative Pharmacology
Head-to-head clinical analysis: EXENATIDE SYNTHETIC versus WEGOVY HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXENATIDE SYNTHETIC versus WEGOVY HD.
EXENATIDE SYNTHETIC vs WEGOVY HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
WEGOVY (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety.
Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.
Subcutaneous injection once weekly. Initiate at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly for 4 weeks, then 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, then maintain at 2.4 mg weekly.
None Documented
None Documented
Terminal elimination half-life is 2.4 hours for subcutaneous administration, supporting twice-daily dosing.
Terminal elimination half-life approximately 165 hours (≈7 days), supporting once-weekly dosing.
Primarily renal via glomerular filtration and proteolytic degradation; approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in urine and feces.
Primarily renal elimination of intact peptide; ~47% excreted unchanged in urine, remainder via fecal/biliary routes (≈38%).
Category A/B
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist